Useful Info for Pharmaceutical Firms and Research Institutes
The Korean Intellectual Property Office announced on Sept. 8 that mRNA vaccine patent analysis reports are available on its patent information navigation website.
With mRNA technology emerging rapidly for treatment of various diseases, the reports on mRNA vaccine-related patent information are expected to serve as useful guidelines for mRNA vaccine development at enterprises and research institutes. The reports currently cover 691 patents made public in or before June this year.
Specifically, the patents include 50 related to antigen optimization, 54 related to mRNA synthesis and modification, 28 related to mRNA separation and purification, 189 related to mRNA-lipid nanoparticle manufacturing, and 61 related to preparation. When it comes to the Moderna, Pfizer and CureVac vaccines, various types of scattered information and data have been collected and analyzed along with key patent information by production process and information on IPR disputes and license statuses.
It takes 18 months for a patent to be made public after application and it takes a lot of time until claims are finalized after domestic application, which means the website will cover more patents on COVID-19 vaccines down the road. “We hope that the mRNA vaccine patent analysis reports will be useful for vaccine development and national R&D related to mRNA drugs,” the office said.